{
    "clinical_study": {
        "@rank": "38477", 
        "arm_group": [
            {
                "arm_group_label": "Arm A: GSK3052230 + paclitaxel/carboplatin", 
                "arm_group_type": "Experimental", 
                "description": "Subject will receive GSK3052230 as 30-minute intravenous (i.v.) infusion once a week (Day 1, Day 8, Day 15) of each 21-day cycle + paclitaxel (constant infusion for 3 hrs) and carboplatin (constant infusion for 30 to 60 minutes) iv on Day 1 of each 21-day cycle. The number of cycles of paclitaxel/carboplatin will be limited to 4 to 6 cycles."
            }, 
            {
                "arm_group_label": "Arm B: GSK3052230 + docetaxel", 
                "arm_group_type": "Experimental", 
                "description": "Subject will receive GSK3052230 as 30-minute intravenous (i.v.) infusion once a week (Day 1, Day 8, Day 15) of each 21-day cycle + docetaxel as 1 hour iv infusion on Day 1 of each 21-day cycle. Subjects may continue to receive docetaxel until disease progression or as long as they are considered to derive benefit from treatment."
            }, 
            {
                "arm_group_label": "Arm C: GSK3052230 + pemetrexed and cisplatin", 
                "arm_group_type": "Experimental", 
                "description": "Subject will receive GSK3052230 as 30 minute iv infusion once a week (Day 1, Day 8, Day 15) of each 21 day cycle + pemetrexed iv infusion over 10 minutes on Day 1 of each 21 day cycle followed 30 minutes later by iv Cisplatin infused over 2 hours"
            }
        ], 
        "brief_summary": {
            "textblock": "This phase IB trial aims to identify anticancer activity of GSK3052230 in subjects with\n      malignancies with abnormal dependence on FGF pathway signaling. Combination doses of\n      GSK3052230 with standard of care chemotherapy in the first and second line setting of\n      metastatic squamous non-small cell lung cancer (NSCLC) will be identified in the 3+3\n      dose-escalation design of the study. This will be a multi-arm, multicenter, non-randomized,\n      parallel-group, uncontrolled, open-label Phase IB study designed to evaluate the safety,\n      tolerability and preliminary activity of GSK3052230 in combination with paclitaxel +\n      carboplatin (Arm A), in combination with docetaxel (Arm B), or in combination with\n      pemetrexed + cisplatin (Arm C). Approximately 70 subjects will be enrolled in the study\n      (approximately up to 120 may be enrolled)."
        }, 
        "brief_title": "Study to Evaluate GSK3052230 in Combination With Paclitaxel and Carboplatin, or Docetaxel or as Single Agent in Subjects With Solid Malignancies and Deregulated Fibroblast Growth Factor (FGF) Pathway Signaling", 
        "completion_date": {
            "#text": "October 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Cancer", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n          -  Signed written informed consent\n\n          -  Histologically or cytologically confirmed diagnosis: Arm A and B- stage IV recurrent\n             metastatic squamous NSCLC with Fibroblast growth factor receptor 1 (FGFR1) gene\n             amplification by central laboratory testing. Arm C- recurrent after local therapy or\n             unresectable MPM with measurable lesions.\n\n        For specific arms the following requirements:\n\n        Arm A: Subjects who have received no prior therapy for Stage IV or recurrent metastatic\n        disease. Note, to avoid any undue delay of initiating systemic chemotherapy for these\n        subjects with newly diagnosed metastatic disease, it is allowed to initiate the first\n        cycle of chemotherapy while eligibility for the study is still being determined, as long\n        as the first dose of GSK3052230 is given no later than Cycle 2 Day 1 of chemotherapy. In\n        addition, subjects with Stage IV disease and recurrence after previous NSCLC that has been\n        treated with surgery and adjuvant chemotherapy or a radio- chemotherapy regimen with\n        curative intent are eligible, provided 6 months has passed since this treatment ended.\n\n        Arm B: Subjects who have documented tumor progression (based on radiological imaging) or\n        intolerability after receiving only one prior line of platinum containing combination\n        chemotherapy for Stage IV or recurrent metastatic disease. Continued 'maintenance'\n        chemotherapy will be considered part of the first line regimen if the same agents are\n        used. If new agents are used for maintenance treatment, this will be considered a second\n        line of therapy. Note: first line treatment should not include docetaxel but may have\n        included paclitaxel.\n\n        Arm C: Subjects who have received no prior systemic therapy for MPM.\n\n        - Availability of archival tumor tissue required for assessment of deregulated FGF pathway\n        signaling e.g. FGFR1 amplification or FGF2 expression. If archival tissue is not\n        available, a fresh biopsy is required. In Arms A and B, subjects will be prospectively\n        screened for FGFR1 gene amplification using a Fluorescence in situ hybridization (FISH)\n        assay. For inclusion in this study, based on the central laboratory testing, FGFR1 gene\n        amplification must meet one of the following criteria: a ratio of FGFR1/CEN 8 of >=2; or\n        average number of FGFR1 signals per tumor nucleus of >=6; or the percentage of tumor\n        nuclei containing >=5 FGFR1 signals is >=50%.\n\n        In Arm C, FGF2 expression by IHC will be evaluated retrospectively in tissue samples by a\n        central laboratory and is not a requirement for study entry.\n\n          -  Measurable disease per RECIST version 1.1\n\n          -  Male or female >=18 years of age.\n\n          -  Women of childbearing potential must have a negative serum pregnancy test within 7\n             days of first dose of study treatment and agree to use effective contraception, from\n             14 days prior to the first dose of study treatment, throughout the study, and for 6\n             months following the last dose of chemotherapy or 4 weeks after the last dose of\n             GSK3052230, whichever is latest. .\n\n          -  Men with a female partner of childbearing potential must have either had a prior\n             vasectomy or agree to use effective contraception for at least 2 weeks prior to\n             administration of the first dose of study treatment and for at least 6 months  after\n             the last dose of chemotherapy  to allow for clearance of any altered sperm.\n\n          -  Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1 for Arm A\n             subjects and 0-2 for Arms B and C\n\n          -  French subjects: In France, a subject will be eligible for inclusion in this study\n             only if either affiliated to or a beneficiary of a social security category\n\n          -  Must have adequate organ function as defined by the following baseline values:\n             Absolute neutrophil count >=1.5 x 10^9/Liter, Hemoglobin >=10 gram (g)/decilitre(dL),\n             Platelets >=100 x 10^9/L, Partial thromboplastin time (PTT) <=1.25 x upper limit of\n             normal (ULN), Albumin >=2.5 g/dL, Serum bilirubin <=1.25 times ULN (for Arm B: <=ULN\n             ), Aspartate aminotransferase (AST) and Alanine aminotransferase (ALT) <=2.5 times\n             ULN (for Arm B: <=1.5 times ULN), Serum Creatinine <=1.5 x ULN, Or Measured or\n             Calculated Creatinine Clearance >=45 mL/min, Left ventricular ejection fraction\n             >=lower limit of normal (LLN).\n\n        Exclusion Criteria\n\n          -  For Arms A, B, C: Treatment with any FGFR inhibitor. For Arms B, C: Treatment with\n             any anti-cancer therapy (for biological anti-cancer therapies see criteria below.)\n             during the preceding 4 weeks or within 4 half-lives of the therapy, whichever is\n             longer.\n\n          -  Receipt of any biological therapy within 6 weeks of the first dose of GSK3052230\n\n          -  Unresolved toxicity of National Cancer Institute Common Terminology Criteria for\n             Adverse Events, version 4.03 (NCI CTCAE version 4.03) Grade 2 or higher from previous\n             anti-cancer therapy, except alopecia.\n\n          -  Active malignancy other than the cancer under study. Subjects with a history of\n             completely resected non-melanomatous skin carcinoma or successfully treated in situ\n             carcinoma are eligible.\n\n          -  Presence of uncontrolled infection\n\n          -  Prior major surgery or trauma within 28 days before first dose of study drug\n\n          -  Presence of any non-healing wound, fracture, or ulcer\n\n          -  Any prohibited medication(s) as described in protocol\n\n          -  Conditions likely to increase the potential for abdominal perforation or fistula\n             formation, including but not limited to:\n\n        Luminal intestinal cancers or bulky abdominal disease. Presence or history of abdominal\n        fistula, gastrointestinal perforation, peptic ulcer disease or intra-abdominal abscess\n        within the six months prior to the first dose of GSK3052230.\n\n        Other risk factors for perforation, such as acute diverticulitis, obstruction or previous\n        abdominal or pelvic radiation.\n\n          -  Symptomatic leptomeningeal or brain metastases or spinal cord compression Note:\n             Subjects previously treated for these conditions are eligible if they meet following\n             two criteria: (1) have had stable CNS disease for at least 4 weeks after local\n             therapy as assessed by imaging (contrast enhanced magnetic resonance imaging (MRI) or\n             computed tomography (CT)), and (2) are asymptomatic and off corticosteroids, or are\n             on stable dose of corticosteroids for at least 4 weeks prior to Day 1..\n\n          -  Have a known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs\n             chemically related to study drugs (GSK3052230, docetaxel, paclitaxel, carboplatin,\n             pemetrexed, cisplatin) and or their excipients that contraindicate their\n             participation.\n\n          -  Known human immunodeficiency virus-positive serology, acquired immunodeficiency\n             syndrome (AIDS), or an AIDS-related illness.\n\n          -  Prior organ or allogeneic stem cell transplant\n\n          -  The following cardiac abnormalities:\n\n        Corrected QT (QTc) interval >=480 millisecond. History of acute coronary syndromes\n        (including unstable angina) within the past 24 weeks Coronary angioplasty or stenting\n        within the past 24 weeks. Class II, III, or IV heart failure as defined by the New York\n        Heart Association (NYHA) functional classification system.\n\n        Abnormal cardiac valve morphology (>= Grade 2) documented by echocardiogram (subjects with\n        Grade 1 abnormalities [i.e., mild regurgitation/stenosis] can be entered on study).\n\n        History of known arrhythmias (except sinus arrhythmia and atrial fibrillation that is\n        controlled) within the past 24 weeks.\n\n          -  Presence or history of hemoptysis (>1/2 teaspoon of red blood) 2 weeks prior to the\n             first dose of GSK3052230\n\n          -  Any serious and/or unstable pre-existing medical, psychiatric disorder or other\n             conditions that could interfere with subject's safety, obtaining informed consent or\n             compliance to the study procedures.\n\n          -  Current active liver or biliary disease (with the exception of Gilbert's syndrome or\n             asymptomatic gallstones, liver metastases or otherwise stable chronic liver disease\n             per investigator's assessment).\n\n          -  Pregnant, lactating or actively breast feeding females.\n\n          -  French subjects: The French subject has participated in any study using an\n             investigational study treatment(s) during the previous 30 days."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "104", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 30, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01868022", 
            "org_study_id": "117360"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Arm A: GSK3052230 + paclitaxel/carboplatin", 
                    "Arm C: GSK3052230 + pemetrexed and cisplatin", 
                    "Arm B: GSK3052230 + docetaxel"
                ], 
                "description": "A clear to opalescent, colorless to pale yellow solution for IV infusion once weekly (Day 1, Day 8, Day 15) in each 21-day cycle with unit dose strengths/dose level of 5, 10, 15, and 20 mg/kg supplied in a sterile 25 mL glass vial.", 
                "intervention_name": "GSK3052230", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Arm A: GSK3052230 + paclitaxel/carboplatin", 
                "description": "paclitaxel will be from commercial stock.", 
                "intervention_name": "paclitaxel", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Arm A: GSK3052230 + paclitaxel/carboplatin", 
                "description": "carboplatin will be from commercial stock.", 
                "intervention_name": "carboplatin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Arm B: GSK3052230 + docetaxel", 
                "description": "docetaxel will be from commercial stock.", 
                "intervention_name": "docetaxel", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Arm C: GSK3052230 + pemetrexed and cisplatin", 
                "description": "pemetrexed will be from  commercial stock", 
                "intervention_name": "pemetrexed", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Arm C: GSK3052230 + pemetrexed and cisplatin", 
                "description": "cisplatin will be from commercial stock", 
                "intervention_name": "cisplatin", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Docetaxel", 
                "Pemetrexed", 
                "Cisplatin", 
                "Carboplatin", 
                "Paclitaxel"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "FGFR1", 
            "FP1039", 
            "GSK3052230", 
            "docetaxel", 
            "FGFR", 
            "carboplatin", 
            "HGS1036", 
            "squamous non-small cell lung cancer", 
            "paclitaxel"
        ], 
        "lastchanged_date": "May 22, 2014", 
        "location": [
            {
                "contact": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "US GSK Clinical Trials Call Center", 
                    "phone": "877-379-3718"
                }, 
                "contact_backup": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "EU GSK Clinical Trials Call Center", 
                    "phone": "+44 (0) 20 8990 4466"
                }, 
                "facility": {
                    "address": {
                        "city": "Scottsdale", 
                        "country": "United States", 
                        "state": "Arizona", 
                        "zip": "85258"
                    }, 
                    "name": "GSK Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "US GSK Clinical Trials Call Center", 
                    "phone": "877-379-3718"
                }, 
                "contact_backup": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "EU GSK Clinical Trials Call Center", 
                    "phone": "+44 (0) 20 8990 4466"
                }, 
                "facility": {
                    "address": {
                        "city": "Chaple Hill", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "27599-7305"
                    }, 
                    "name": "GSK Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "US GSK Clinical Trials Call Center", 
                    "phone": "877-379-3718"
                }, 
                "contact_backup": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "EU GSK Clinical Trials Call Center", 
                    "phone": "+44 (0) 20 8990 4466"
                }, 
                "facility": {
                    "address": {
                        "city": "Leuven", 
                        "country": "Belgium", 
                        "zip": "3000"
                    }, 
                    "name": "GSK Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "US GSK Clinical Trials Call Center", 
                    "phone": "877-379-3718"
                }, 
                "contact_backup": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "EU GSK Clinical Trials Call Center", 
                    "phone": "+44 (0) 20 8990 4466"
                }, 
                "facility": {
                    "address": {
                        "city": "Koebenhavn Oe", 
                        "country": "Denmark", 
                        "zip": "2100"
                    }, 
                    "name": "GSK Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "US GSK Clinical Trials Call Center", 
                    "phone": "877-379-3718"
                }, 
                "contact_backup": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "EU GSK Clinical Trials Call Center", 
                    "phone": "+44 (0) 20 8990 4466"
                }, 
                "facility": {
                    "address": {
                        "city": "Marseille Cedex 5", 
                        "country": "France", 
                        "zip": "13385"
                    }, 
                    "name": "GSK Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "US GSK Clinical Trials Call Center", 
                    "phone": "877-379-3718"
                }, 
                "contact_backup": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "EU GSK Clinical Trials Call Center", 
                    "phone": "+44 (0) 20 8990 4466"
                }, 
                "facility": {
                    "address": {
                        "city": "Toulouse Cedex 9", 
                        "country": "France", 
                        "zip": "31059"
                    }, 
                    "name": "GSK Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "US GSK Clinical Trials Call Center", 
                    "phone": "877-379-3718"
                }, 
                "contact_backup": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "EU GSK Clinical Trials Call Center", 
                    "phone": "+44 (0) 20 8990 4466"
                }, 
                "facility": {
                    "address": {
                        "city": "St. Petersburg", 
                        "country": "Russian Federation", 
                        "zip": "197 089"
                    }, 
                    "name": "GSK Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "US GSK Clinical Trials Call Center", 
                    "phone": "877-379-3718"
                }, 
                "contact_backup": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "EU GSK Clinical Trials Call Center", 
                    "phone": "+44 (0) 20 8990 4466"
                }, 
                "facility": {
                    "address": {
                        "city": "St. Petersburg", 
                        "country": "Russian Federation", 
                        "zip": "197758"
                    }, 
                    "name": "GSK Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "US GSK Clinical Trials Call Center", 
                    "phone": "877-379-3718"
                }, 
                "contact_backup": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "EU GSK Clinical Trials Call Center", 
                    "phone": "+44 (0) 20 8990 4466"
                }, 
                "facility": {
                    "address": {
                        "city": "Badajoz", 
                        "country": "Spain", 
                        "zip": "06080"
                    }, 
                    "name": "GSK Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "US GSK Clinical Trials Call Center", 
                    "phone": "877-379-3718"
                }, 
                "contact_backup": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "EU GSK Clinical Trials Call Center", 
                    "phone": "+44 (0) 20 8990 4466"
                }, 
                "facility": {
                    "address": {
                        "city": "Barcelona", 
                        "country": "Spain", 
                        "zip": "08035"
                    }, 
                    "name": "GSK Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "US GSK Clinical Trials Call Center", 
                    "phone": "877-379-3718"
                }, 
                "contact_backup": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "EU GSK Clinical Trials Call Center", 
                    "phone": "+44 (0) 20 8990 4466"
                }, 
                "facility": {
                    "address": {
                        "city": "Barcelona", 
                        "country": "Spain", 
                        "zip": "08028"
                    }, 
                    "name": "GSK Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "US GSK Clinical Trials Call Center", 
                    "phone": "877-379-3718"
                }, 
                "contact_backup": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "EU GSK Clinical Trials Call Center", 
                    "phone": "+44 (0) 20 8990 4466"
                }, 
                "facility": {
                    "address": {
                        "city": "Madrid", 
                        "country": "Spain", 
                        "zip": "28034"
                    }, 
                    "name": "GSK Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "US GSK Clinical Trials Call Center", 
                    "phone": "877-379-3718"
                }, 
                "contact_backup": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "EU GSK Clinical Trials Call Center", 
                    "phone": "+44 (0) 20 8990 4466"
                }, 
                "facility": {
                    "address": {
                        "city": "Sevilla", 
                        "country": "Spain", 
                        "zip": "41013"
                    }, 
                    "name": "GSK Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "US GSK Clinical Trials Call Center", 
                    "phone": "877-379-3718"
                }, 
                "contact_backup": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "EU GSK Clinical Trials Call Center", 
                    "phone": "+44 (0) 20 8990 4466"
                }, 
                "facility": {
                    "address": {
                        "city": "London", 
                        "country": "United Kingdom", 
                        "zip": "W1G 6AD"
                    }, 
                    "name": "GSK Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Belgium", 
                "Denmark", 
                "France", 
                "Russian Federation", 
                "Spain", 
                "United Kingdom"
            ]
        }, 
        "number_of_arms": "3", 
        "official_title": "Multi-arm, Non-randomized, Open-Label Phase IB Study to Evaluate GSK3052230 in Combination With Paclitaxel and Carboplatin, or Docetaxel or as Single Agent in Subjects With Solid Malignancies and Deregulated FGF Pathway Signaling", 
        "overall_contact": {
            "email": "GSKClinicalSupportHD@gsk.com", 
            "last_name": "US GSK Clinical Trials Call Center", 
            "phone": "877-379-3718"
        }, 
        "overall_official": {
            "affiliation": "GlaxoSmithKline", 
            "last_name": "GSK Clinical Trials", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "France: National Agency for the Safety of Medicine and Health Products", 
                "Denmark: Danish Medicines Agency", 
                "Spain: Spanish Agency for Medicines and Health Products", 
                "United States: Food and Drug Administration"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "October 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "AEs will be collected from the time the first dose of study treatment is administered until 30 days following discontinuation of study treatment regardless of initiation of a new cancer therapy or transfer to hospice. Severity of AEs will be graded utilizing the National Cancer Institute- Common Terminology Criteria for AEs (NCI-CTCAE) version 4.03", 
                "measure": "Rate and severity of adverse events (AEs) as a measure of safety and tolerability", 
                "safety_issue": "No", 
                "time_frame": "Up to 6 months"
            }, 
            {
                "measure": "Number of Participants withdrawn due to AEs as measure of safety and tolerability", 
                "safety_issue": "No", 
                "time_frame": "Up to 6 months"
            }, 
            {
                "measure": "Dose interruptions and reduction as a measure of safety and tolerability", 
                "safety_issue": "No", 
                "time_frame": "Up to 6 months"
            }, 
            {
                "measure": "Treatment duration as a measure of safety and tolerability", 
                "safety_issue": "No", 
                "time_frame": "Up to 6 months"
            }, 
            {
                "description": "DLT: Toxicity due to GSK3052230 its combination with chemotherapy within Cycle 1 that are unlikely to be due to another cause ( known effects of cytotoxic chemotherapy, disease progression, or accident according to the following criteria: Grade 3 or 4 clinically significant non-hematological toxicity, Grade 4 neutropenia lasting more than 7 days, Grade 4 febrile Neutropenia, Grade 4 thrombocytopenia, Grade 4 clinically significant lab abnormalities with duration greater than 48hrs, Treatment delay of 14 days or greater due to unresolved drug-related toxicity, and any grade 2 toxicity", 
                "measure": "Dose limiting toxicity (DLT) as a measure of safety and tolerability", 
                "safety_issue": "No", 
                "time_frame": "Cycle 1 (first 21 days of study treatment)."
            }, 
            {
                "description": "Vital signs include: systolic blood pressure, diastolic blood pressure, temperature, respiration rate and pulse rate. Vital signs will be measured after subject resting for at least 5 minutes in a semi-supine position.", 
                "measure": "Change from baseline in vital sign as a measure of safety and tolerability", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Day 1 of each treatment cycle (Up to 6 months)."
            }, 
            {
                "description": "12-lead ECGs will be obtained at designated time points during the study using an ECG machine that automatically calculates the heart rate and measures PR, QRS, QT, and corrected QT (QTc) intervals.", 
                "measure": "Change from baseline in 12-lead electrocardiogram (ECG) as a measure of safety and tolerability", 
                "safety_issue": "No", 
                "time_frame": "Up to 6 months"
            }, 
            {
                "description": "ECHOs will be performed at baseline to assess cardiac ejection fraction and cardiac valve morphology for the purpose of study eligibility and Cycle 4. Evaluation of ECHO will include evaluation for left ventricular ejection fraction (LVEF) and both right and left-sided valvular lesions.", 
                "measure": "Change from baseline in Echocardiogram (ECHO) as measure of safety and tolerability", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Cycle 4 (Day 60)."
            }, 
            {
                "description": "Laboratory parameters include: hematology, urinalysis, clinical chemistry and additional parameters", 
                "measure": "Change from baseline in laboratory test as measure of safety and tolerability", 
                "safety_issue": "No", 
                "time_frame": "Baseline and up to 6 months"
            }, 
            {
                "description": "The MTD for the combination regimens in Arm A and B will be defined as the highest dose level tested at which < 33% of subjects experience a DLT.", 
                "measure": "Maximum tolerated dose (MTD) or maximum feasible dose (MFD) of GSK3052230 in arm A and B", 
                "safety_issue": "No", 
                "time_frame": "Up to 6 months"
            }, 
            {
                "description": "Best response defined as complete or partial response, stable disease or progressive disease according to RECIST 1.1", 
                "measure": "Best response according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1", 
                "safety_issue": "No", 
                "time_frame": "Up to 6 months"
            }, 
            {
                "description": "ORR defined as the proportion of subjects with investigator-assessed confirmed complete response or partial response per RECIST 1.1 or modified RECIST for Malignant pleural mesothelioma (MPM)", 
                "measure": "Overall response rate (ORR) per RECIST 1.1 or modified RECIST", 
                "safety_issue": "No", 
                "time_frame": "Up to 6 months"
            }, 
            {
                "description": "Physical examinations include will include assessments of the head, eyes, ears, nose, throat, skin, thyroid, neurological, lungs, cardiovascular, abdomen (liver and spleen), lymph nodes and extremities. Height and weight will also be measured and recorded", 
                "measure": "Change from baseline in physical examination parameters.", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Up to follow up visit (7 months)."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01868022"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "PFS is defined as the interval between first dose of GSK3052230 and the earliest date of disease progression or death due to any cause by investigator assessment per RECIST 1.1 or modified RECIST for MPM", 
                "measure": "Progression-free survival (PFS) by investigator assessment per RECIST 1.1 or modified  RECIST", 
                "safety_issue": "No", 
                "time_frame": "Up to 6 months"
            }, 
            {
                "description": "GSK3052230 population PK parameters include: systemic clearance of parent drug (CL) and apparent volume of distribution after IV administration (Vd), and relevant covariates which may influence exposure (e.g. age, weight, or disease related covariates)", 
                "measure": "GSK3052230 population pharmacokinetic (PK) profile", 
                "safety_issue": "No", 
                "time_frame": "Up to 6 months"
            }, 
            {
                "description": "FVC will be measured to to assess improvement in pulmonary function in subject with MPM in arm C only", 
                "measure": "Change from baseline in Forced Vital Capacity (FVC) in subjects  with MPM", 
                "safety_issue": "No", 
                "time_frame": "Up to 6 months"
            }
        ], 
        "source": "GlaxoSmithKline", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "GlaxoSmithKline", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}